Fuda Cancer Hospital
Lung cancer treatment cost in China typically depends on the diagnostic accuracy of procedures such as a CT of the chest, which ranges from $300 to $600. Primary surgical interventions, including lung cancer surgery, run from $24,500 to $43,500, while advanced options like lobectomy cost $22,500 to $38,500. Total expenses are determined by the cancer stage and hospital tier, offering 40-60% savings compared to the US. Key centers are in Guangzhou, Xiamen, and Shanghai.
Typical Lung Cancer Treatment Costs in China
Bookimed Expert Insight: Advanced-stage patients often require specialized therapies like cryosurgery or NanoKnife. Fuda Cancer Hospital provides these minimally invasive options for complex cases. Dr. Niu Lizhi has successfully performed nearly 10,000 cryosurgeries for multi-stage oncology. Patients seeking precision radiotherapy benefit from JCI-accredited centers in Xiamen or Guangzhou. Expert-led wards focus on evidence-based protocols to maximize patient comfort and clinical outcomes.
| China | Turkey | Austria | |
| Tomotherapy | from $17,500 | from $12,000 | from $30,000 |
| Stereotaxic radiosurgery | from $8,500 | from $4,500 | from $17,000 |
| Radiotherapy for lung cancer | from $13,500 | from $4,000 | from $6,863 |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
| Pneumonectomy | from $24,000 | from $10,872 | from $50,000 |
Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.
He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.
Nearly 10,000 cryosurgeries performed – Prof. Niu Lizhi leads Fuda Cancer Hospital's minimally invasive oncology program.
Dr. Liuying directs the Oncology Ward at Jinshazhou Hospital in Guangzhou. She specializes in minimally invasive ablation for liver, lung, and colorectal cancers. Her primary focus includes hepatocellular carcinoma and melanoma liver metastasis. Dr. Liuying contributed to the national expert consensus on thermal ablation for lung tumors.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Written by Mariia Mytrofankina
China provides high-quality lung cancer care through specialized oncology centers in Guangzhou, Shanghai, and Beijing. These JCI-accredited facilities offer advanced technologies like CyberKnife M6 and NanoKnife. High patient volumes allow surgeons to achieve remarkable procedural mastery in minimally invasive thoracic surgeries.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital treat 30,000+ international patients yearly. This massive data pool helps specialists refine protocols for advanced stages. Dr. Liuying at Jinshazhou Hospital even contributed to national expert consensus on lung tumor ablation. This level of specialization ensures that doctors see more complex cases in one month than many Western surgeons see in a year.
Patient Consensus: Patients note that top-tier care often rivals Western standards, especially for targeted therapies. They recommend hiring a private Mandarin translator and utilizing VIP departments to navigate language barriers effectively.
Advanced lung cancer therapies in China center on next-generation immunotherapy and high-precision minimally invasive procedures. Facilities utilize domestic breakthroughs like Ivonescimab alongside international standards. Molecularly targeted drugs for EGFR and ALK mutations are widely available. Treatment often integrates CyberKnife M6 radiosurgery and specialized cryosurgical ablation.
Bookimed Expert Insight: A major advantage for lung cancer patients in China is the massive scale of specialized centers. Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries. This high volume often translates to expertise in treating late-stage cancers. Patients can access specific technologies like NanoKnife that are less common in standard European or North American protocols.
Patient Consensus: Patients value the speed of enrollment for clinical trials and the affordability of genomic testing. Many suggest using official hospital mobile apps for scheduling to streamline care during their stay.
Top-tier Chinese hospitals for lung cancer treatment include JCI-accredited centers like Fuda Cancer Hospital and the Cancer Hospital of the Chinese Academy of Medical Sciences. These institutions offer advanced therapies such as cryosurgery, NanoKnife, and CyberKnife M6. They follow international NCCN guidelines while processing high patient volumes.
Bookimed Expert Insight: While high-profile national centers in Beijing handle massive volumes, private JCI-accredited hospitals like Fuda Cancer Hospital offer a significant coordination advantage. Dr. Niu Lizhi at Fuda has performed nearly 10,000 cryosurgeries. This specific procedural experience often exceeds that of western specialists. Choosing a clinic with such high individual doctor case numbers can lead to better precision in complex, minimally invasive lung procedures.
Patient Consensus: Patients note that while medical technology is advanced, having a professional coordinator is vital for navigating language barriers. Many emphasize that the high surgical volume translates to very experienced thoracic teams and modern immunotherapy options.
International patients manage lung cancer treatment in China through dedicated international departments providing on-site interpreters and logistical support. Facilities like Fuda Cancer Hospital serve over 30,000 global patients. Specialized coordinators handle medical visa invitations, airport transfers, and local housing to ensure seamless clinical transitions.
Bookimed Expert Insight: While many think Tier-1 cities are the only option, Guangzhou has emerged as a specialized hub for lung cancer. Fuda Cancer Hospital and Jinshazhou Hospital offer advanced technologies like Cryosurgery and CyberKnife M6. These centers prioritize international patients, with surgeons like Dr. Niu Lizhi having performed nearly 10,000 cryosurgeries.
Patient Consensus: Patients emphasize that hiring a private medical interpreter is essential for accurate dosing. They also suggest joining digital expat networks to navigate mobile payments and high-speed rail travel successfully.
International patients can secure remote second opinions for lung cancer treatment in China through virtual consultations or written reports. Leading facilities in Guangzhou and Shanghai use telemedicine to review pathology slides and CT scans. This process establishes treatment protocols and provides cost clarity before patients commit to international travel.
Bookimed Expert Insight: Bookimed data shows that packages for advanced therapies, such as the CyberKnife M6 at Jinshazhou Hospital, often include the initial video or text consultation as a standard service. This allows patients to confirm the technical feasibility of stereotactic radiosurgery before arrival. Dr. Zhang Yanjun and other specialists at this facility integrate these remote screenings to ensure the 56,000 CNY treatment cost is medically justified for the specific tumor stage.
Patient Consensus: Patients emphasize that sharing digital pathology slides is essential for accurate remote reviews. Many note that high-volume centers like Fuda Cancer Hospital provide preliminary assessments via digital channels to help clarify complex cases early.
China offers lung cancer treatment through a distinct blend of ablative technologies and integrated traditional therapies. Major centres specialise in minimally invasive alternatives to chemotherapy. Examples include NanoKnife and cryosurgery. Surgeons often combine these with precision radiotherapy or immunotherapy for complex, late-stage cases.
Bookimed Expert Insight: Chinese oncology centres focus heavily on interventional alternatives for patients who cannot undergo standard surgery. For instance, Dr Liuying at Jinshazhou Hospital specialises in radioactive seed implantation and microwave ablation. These techniques allow specialists to target tumours directly. This level of interventional variety is rarely found in single Western units. This approach provides options for cases often deemed untreatable elsewhere.
China offers lung cancer therapies including antibody-drug conjugates, domestic immunotherapy, and precision radiosurgery مثل CyberKnife M6. Specialists use minimally invasive techniques such as NanoKnife and cryosurgery for late-stage cases. JCI-accredited facilities in Guangzhou and Shenzhen provide these treatments alongside clinical trials.
Bookimed Expert Insight: Chinese oncology centres like Fuda Cancer Hospital often focus on alternatives to traditional chemotherapy. They specialise in combining minimally invasive methods like cryosurgery with local interventional therapy. Dr Niu Lizhi has performed nearly 10,000 cryosurgeries. This high volume leads to high local control rates for advanced lung tumours.
Patient Consensus: Patients in China suggest requesting full molecular profiling for EGFR and ALK mutations before starting therapy. They also recommend bringing all pathology and imaging records in English. This helps the medical team coordinate follow-up care with GPs back in Australia.
China leads in CAR-T manufacturing efficiency. It uses automated platforms to reduce production cycles to 24–36 hours. This rapid turnaround significantly cuts the typical multi-week wait. Costs for commercial treatments remain up to 70% lower than in Western countries. This is due to modular manufacturing and streamlined regulatory pathways.
Bookimed Expert Insight: National averages show fast turnaround, but efficiency depends on a clinic's internal infrastructure. Centres like Fuda Cancer Hospital serve over 30,000 international patients, showing highly refined logistics. Choosing a hospital with JCI accreditation ensures that rapid manufacturing meets global safety standards for handling patient cells.
Patient Consensus: Patients note that personalised treatment still requires time for infection control and eligibility checks. Many find that centres managing the entire pipeline provide the most predictable timelines in China.
International patients can access lung cancer clinical trials in China. The country uses a dual-track regulatory system. This allows overseas patients to enrol in experimental studies for immunotherapies and targeted drugs. Specialised clinics in Guangzhou and Shenzhen manage these protocols alongside standard treatments.
Bookimed Expert Insight: Many centres offer standard care, but choosing a facility with a Clinical Research Office is vital. Dr Luan Tianyan in Shenzhen previously worked at the Dana-Farber Cancer Institute in the USA. This training helps bridge the gap between Western standards and Chinese clinical trial requirements. Patients should target institutions where senior staff have Western research backgrounds to simplify eligibility checks.
Patient Consensus: International patients note that enrolment is not straightforward. It depends heavily on pathology reviews and visa logistics. Local coordinators or translators are often necessary to manage paperwork and evaluations at major hospitals in China.
China leads lung cancer care through major centres in Shanghai and Guangzhou. These facilities specialise in high-volume thoracic surgery and specialised therapies. Key institutions like Fuda Cancer Hospital and Shanghai Pulmonary Hospital offer JCI-accredited care. They provide robotic-assisted surgery and minimally invasive treatments for late-stage cases.
Bookimed Expert Insight: Public centres in Shanghai handle the highest surgical volumes. However, private JCI-accredited hospitals in Guangzhou offer better access to niche technologies. Dr Niu Lizhi at Fuda Cancer Hospital has performed nearly 10,000 cryosurgeries. This provides an alternative for patients who cannot undergo traditional open surgery.
Patient Consensus: Patients recommend choosing large dedicated cancer centres over regional hospitals for complex lung cases. They advise prioritising facilities with multidisciplinary tumour boards and international departments to help manage treatment coordination.